Night Shift Work, Cancer Risk, and What the Evidence Can Prove

Night shift work has enough evidence behind it to warrant serious occupational-health attention, but not enough to calculate how many cancers it causes each year. The International Agency for Research on Cancer (IARC) classifies night shift work as Group 2A, meaning it is probably carcinogenic to humans. That classification has persisted since IARC's 2007 review and its 2019 reassessment.

The distinction matters. "Probably carcinogenic" does not mean every night-shift worker will develop cancer, nor does it provide an individual's absolute risk. It means the evidence raises a credible concern: disrupting the body's circadian timing system can plausibly contribute to cancer development, and human studies point in the same direction often enough that IARC considers the hazard probable.

That is a more sober—and more useful—message than pretending science has already produced a precise global bill for working after dark.

Why IARC put night shift work in Group 2A

IARC's Group 2A category is not a ranking of everyday danger. It is a hazard classification based on reviews of human epidemiology, animal research, and mechanistic evidence. As Vivarelli et al. (2026) describe, night shift work received the designation because of strong mechanistic evidence and suggestive human epidemiology. Healthcare, transportation, manufacturing, and security are among the sectors where the exposure commonly occurs.

Night shift work sits in the same IARC group as red meat, anabolic steroids, and glyphosate. That comparison can attract headlines, but it does not mean these exposures carry equal risks. IARC groups describe confidence that an exposure can cause cancer under some circumstances; they do not compare the size of the risk at a given dose or duration.

The strongest recurring signals involve breast, prostate, and colorectal cancers. Reviews also discuss lung cancer, but that evidence requires special caution because smoking, socioeconomic conditions, and work histories can differ sharply between night and day workers.

A plausible biological route is not the same as a measured cancer burden

The body's central clock coordinates sleep, hormone release, metabolism, immune activity, and cellular repair. Night work can put behavior and light exposure at odds with that schedule. The leading biological explanations fit together, although researchers still cannot assign a precise share of cancer risk to each one.

• Melatonin suppression: Artificial light at night, particularly blue-spectrum light, suppresses melatonin. Barboza et al. (2025) reviewed evidence linking prolonged artificial light exposure with melatonin suppression, circadian disruption, and cancer-related pathways. Melatonin has antioxidant and immune-modulating actions and can inhibit estrogen-driven signaling relevant to breast cancer.
• Clock-gene disruption: Misalignment in genes including CLOCK, BMAL1, PER, and CRY may interfere with cell-cycle checkpoints.
• DNA repair: Circadian timing helps coordinate the response to DNA damage. Disruption could impair repair when cells need it.
• Immune surveillance: Circadian disruption has been associated with reduced natural killer-cell activity and weaker innate immune surveillance.
• Oxidative stress: Melatonin suppression may increase reactive oxygen species, creating conditions that can favor carcinogenesis.

These pathways make the hypothesis biologically credible. They do not prove that a particular worker's cancer arose from a schedule, and they do not make melatonin supplements a proven countermeasure. Biology supplies a plausible route; population studies must still show how much traffic actually travels it.

What the human evidence shows—and where it breaks down

A 2025 systematic review by Clemente-Suarez et al. included 75 studies on circadian disruption and cancer. The review used PRISMA methods and Newcastle-Ottawa Scale quality assessments; included studies scored 6 to 9, and 68% scored at least 7. It linked circadian disruption with elevated risks across breast, prostate, and colorectal cancer and identified melatonin suppression, clock-gene disruption, impaired DNA repair, immune dysregulation, and oxidative stress as recurring explanations.

Quality screening helps, but it cannot repair the central measurement problem. Studies define "night shift work" differently: shift start time, hours worked, rotation pattern, and cumulative exposure can all vary. A person who works a few overnight shifts each month is not necessarily comparable with a nurse on permanent nights for decades. Pooling those experiences can blur a dose-response relationship before the analysis begins.

Vivarelli and colleagues screened 312 records and retained 161 peer-reviewed studies focused on night shift work and breast cancer. Their conclusion was appropriately guarded: epidemiological findings have often been inconsistent, in part because studies use retrospective exposure reports, classify shifts differently, and adjust unevenly for confounders. Smoking, alcohol use, obesity, socioeconomic conditions, and the healthy-worker effect can each distort comparisons between night and day workers.

The evidence supports concern about a carcinogenic hazard. It does not yet provide a reliable global count of cancers attributable to night shift work.

The individual studies illustrate both breadth and uncertainty. A Norwegian Offshore Petroleum Workers cohort study examined night shift work and aggressive prostate cancer in an industrial workforce. A Chinese case-control study examined night shift work alongside artificial light at night, sleep duration, and clock-gene polymorphisms in relation to breast cancer risk. Because these circadian disruptors travel together, the study design has difficulty isolating the contribution of shift work itself.

A French population-based case-control study evaluated sleep traits, night shift work, and lung cancer risk among women. Lung cancer broadens the signal but also sharpens the confounding problem: smoking and social conditions could explain part of an association unless they are measured and controlled with unusual care.

The research also matters after diagnosis. A 2023 systematic review of breast cancer survivors found associations between circadian-disrupting behaviors and worse post-diagnosis outcomes. Those findings deserve follow-up, but they do not establish that correcting circadian disruption improves survival.

Why the economic claim remains unproven

Colorectal cancer alone caused 1,931,590 new cases worldwide in 2020, according to figures cited in Guo et al. (2025). Europe had an age-standardized incidence rate of 30.4 per 100,000, compared with 8.4 to 9.1 in Africa and the Eastern Mediterranean region; high-income countries had an incidence rate of 30.2 versus 8.8 in low-income countries.

Those are cancer-burden figures, not figures attributable to night shifts. The available literature does not provide pooled risk ratios or odds ratios with confidence intervals suitable for population-attributable-fraction calculations. It also lacks a verified global denominator for night-shift workers, cost-per-case estimates, and policy evaluations that test whether schedule redesign, workplace-lighting changes, or screening programs reduce cancer outcomes. Calling this a trillion-dollar occupational hazard would require precisely the data that have not yet been produced.

What workers and employers can reasonably do now

Workers should treat long-term night work as an exposure worth discussing with an occupational-health clinician, especially when it is rotating or permanent. Employers can reduce avoidable circadian disruption through more predictable schedules and by examining workplace-lighting practices. These are sensible risk-management steps, not proven cancer-prevention treatments.

Research needs standardized exposure definitions and large prospective cohorts that use verified work schedules rather than memory alone. Those studies should report cancer-site-specific risk estimates with usable uncertainty intervals. Only then can researchers estimate attributable cases, test interventions, and judge whether compensation or regulatory policies improve health.

For now, the evidence supports neither panic nor complacency. Night shift work has a credible carcinogenic signal, a durable IARC Group 2A classification, and real gaps in the epidemiology needed to turn that signal into a precise public-health ledger.